Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $0.95
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Jun 20, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jan 22, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| May 14, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 4, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Mar 20, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jan 3, 24 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 4, 23 |
Daily · Wilder smoothing
| HC Wainwright & Co. |
| maintain |
| Buy |
| Buy |
| Oct 4, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
| Aug 15, 23 | HC Wainwright & Co. | maintain | Buy | Buy |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 34.30 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 10.46 | Oscillator | Buy |
| Williams %R (14) | -81.82 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.05 (Hist -0.02) | Oscillator | Strong Sell |
| Average Directional Index (14) | 24.40 (+DI 15.2 / -DI 18.0) | Trend | Sell |
| EMA 20 | 1.03 | MA | Strong Sell |
| SMA 20 | 1.06 | MA | Strong Sell |
| EMA 50 | 1.07 | MA | Strong Sell |
| SMA 50 | 1.12 | MA | Strong Sell |
| SMA 200 | 1.11 | MA | Strong Sell |
TTM vs. 5-year historical average (annual ratios)
| Metric | COCP | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | -1.2x | -182.5x · sector 20.7x | Discount |
| Forward P/E (FY26E) | -1.3x | EPS est. -0.73 | In line |
| Price / Book | 12.5x | 1.1x | Elevated |
| Price / Sales | 55.5x | — | n/a |
| EV / EBITDA | -1.8x | 0.0x | Discount |
| Return on equity | -207.5% | — | Weak |
| Gross margin | 100.0% | 0.0% | n/a |
| Debt / Equity | 1.28 | 0.10 | Moderate |
| Piotroski / Altman Z | 3/9 | Z -108.45 | Distress |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Sep 9, 2026 | 2026-09-09 08:00:19 | View |
| 3 | Aug 21, 2026 | 2026-08-21 16:10:21 | View |
| 8-K | Aug 18, 2026 | 2026-08-18 16:30:32 | View |
| 8-K | Aug 17, 2026 | 2026-08-17 16:15:41 | View |
| 10-Q | Aug 13, 2026 | 2026-08-13 07:29:56 | View |
| SC 13D | Aug 7, 2026 | 2026-08-07 19:49:47 | View |
| SC 13D/A | Aug 7, 2026 | 2026-08-07 17:11:56 | View |
| 4 | Aug 6, 2026 | 2026-08-06 17:11:40 | View |
| 4 | Aug 5, 2026 | 2026-08-05 16:10:26 | View |
| 8-K | Aug 3, 2026 | 2026-08-03 07:15:25 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Aug 12, 26 | Brosgart Carol L | director: | 0 | — | |
| Aug 5, 26 | Frost Phillip Md Et Al | director, 10 percent owner: | P-Purchase | 10,000 @ $0.9816 | $9.82K |
| Aug 3, 26 | Frost Phillip Md Et Al | director, 10 percent owner: | P-Purchase | 75,000 @ $0.9412 | $70.59K |
| Jun 3, 26 | Sapirstein James | officer | 0 | — | |
| Feb 24, 26 | Frost Phillip Md Et Al | director, 10 percent owner: | P-Purchase | 20,000 @ $0.9976 | $19.95K |
| Feb 6, 26 | Frost Phillip Md Et Al | director, 10 percent owner: | P-Purchase | 50,000 @ $0.9456 | $47.28K |
| Jan 9, 26 | Kornberg Roger D. | director | A-Award | 24,615 @ $1.10 | $27.08K |
| Jan 9, 26 | Pfenniger Richard C Jr | director | A-Award | 16,410 @ $1.10 | $18.05K |
Stock news · updated daily
No serious adverse events reported to date Preliminary efficacy results expected in late 2026 or early 2027 MIAMI, Fla. And BOTHELL, Wash.
BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.
Longtime investor OPKO Health increases its position as Cocrystal advances toward norovirus Phase 1b data in late 2026 BOTHELL, Wash., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a biotechnology company developing novel antiviral therapeutics, today announced a $5 million investment from OPKO Health, Inc. (Nasdaq: OPK) (“OPKO”), a longtime investor in the Company, has increased its position through a $5 million investment as the Company advances its lead norovirus program toward Phase 1b topline data later this year.
Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cocrystal Pharma (NASDAQ: COCP - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation. Institutional and Insider Ownership 35.0% of Zevra
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.17 | -0.23 | Miss -39.4% | $100.0K |
| May 15, 2026 | -0.15 | -0.17 | Miss -13.3% | $100.0K |
| Mar 31, 2026 | -0.18 | -0.17 | Beat 5.6% | — |
| Nov 14, 2025 | -0.22 | -0.19 | Beat 13.6% | — |
| Aug 14, 2025 | -0.30 | -0.20 | Beat 33.3% | — |
| May 15, 2025 | -0.52 | -0.23 | Beat 55.8% | — |